AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
Turning AI skeptics into AI advocates through high-integrity data